Application of cannabidiol analogue CIAC001 in preparation of medicine for treating Alzheimer's disease

Abstract

The invention discloses application of a cannabidiol analogue CIAC001 in preparation of a medicine for treating Alzheimer's disease, and relates to the technical field of medicine. The application comprises the following steps: step 1, medicine extraction: extracting CIAC001, an NMDA receptor antagonist and a cholinesterase inhibitor according to a ratio of 1: 5: 5 into a medicine carrying needle cylinder; 2, medicine heating, wherein a heating assembly is started to conduct pulse heating on the medicine in the medicine carrying needle cylinder; 3, nursing the patient: heating and nursing the injection part of the patient by using a nursing assembly; 4, medicine injection: pushing a pushing head, puncturing a needle into the injection part of the patient, and injecting the medicine into the body of the patient; and 5, observing and treating side reactions: taking down the injection device after the drug reaction is complete, observing the side reaction condition of the patient, and starting a temperature regulator to cool the patient. The medicine activity can be effectively improved, side effects of the medicine on patients are reduced, and therefore the treatment effect of the medicine is enhanced.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and specifically to the use of a cannabidiol analog CIAC001 in the preparation of a drug for treating Alzheimer's disease. Background Art

[0002] The application of cannabidiol analog CIAC001 in the preparation of drugs for the treatment of Alzheimer's disease has been experimentally confirmed. This analog has been found to improve cognitive impairment and learning and memory decline in Alzheimer's disease models. Specifically, CIAC001 has been shown to effectively enhance the synaptic plasticity of Alzheimer's mice through synaptic long-term potentiation (LTP) detection, thereby enhancing their exploration ability, learning and memory ability, and cognitive ability, and helping to relieve anxiety.

[0003] Alzheimer's disease is a neurodegenerative disease that is mainly manifested by memory impairment, language impairment, and cognitive impairment. Its onset is related to multiple factors, including amyloid β deposition and tau protein hyperphosphorylation. The therapeutic mechanism of CIAC001 includes increasing hippocampal synaptic plasticity, protecting neuronal integrity, and reducing Alzheimer's disease-related pathology in the hippocampus, thereby improving related symptoms.

[0004] CIAC001 has shown potential in the preparation of drugs for the treatment of Alzheimer's disease, but it is still in the research stage. Since drugs have different activities at different temperatures, existing treatments are basically conducted at room temperature, without considering the activity and effect of drugs at different temperatures, resulting in poor treatment effects.

[0005] Therefore, the present invention provides an application of a cannabidiol analog CIAC001 in the preparation of a drug for treating Alzheimer's disease, and through the control of temperature, the drug activity can be stimulated to achieve better therapeutic effects. Summary of the invention

[0006] In order to solve the problem of lack of temperature control during the preparation and treatment of cannabidiol analog CIAC001, the present invention provides the use of cannabidiol analog CIAC001 in the preparation of drugs for treating Alzheimer's disease. The design of the heating component increases the temperature control of the cannabidiol analog CIAC001 during the preparation and treatment, thereby improving the activity and bioavailability of the drug.

[0007] In order to achieve the above object, the technical scheme of the present invention is as follows: Use of cannabidiol analog CIAC001 in the preparation of a drug for treating Alzheimer's disease comprises the following steps:

[0008] Step 1, drug extraction: CIAC001, NMDA receptor antagonist and cholinesterase inhibitor were extracted into the injection device at a ratio of 1:5:5;

[0009] Step 2, heating the medicine: starting the heating component to pulse heat the medicine in the injection device to heat the medicine to a specified temperature value;

[0010] Step 3: Patient care: heating care of the patient's injection site;

[0011] Step 4: Injection of the drug: Aim at the injection site of the patient and inject the drug into the patient's body;

[0012] Step 5. Observation and treatment of side effects: Observe the side effects of the patient and cool down the patient.

[0013] Furthermore, in step five, adverse reactions refer to reactions caused by side effects of drugs, including dizziness, vomiting, diarrhea, and physical fatigue.

[0014] Furthermore, in step five, the temperature regulator is connected to the controller signal. When the patient is not observed to experience dizziness, vomiting, diarrhea and physical fatigue, the indoor temperature is kept unchanged. When the patient has side effects, the indoor temperature is lowered to 26-16 degrees according to the degree of the patient's side effects.

[0015] The principles and beneficial effects of the basic solution are: 1. When the heating component is started, the heating component converts electrical energy into thermal energy, and evenly heats the drug in the drug-loaded syringe in a short time. After the drug is heated, it can effectively enhance the activity of the drug and better stimulate the efficacy. CIAC001 can better increase the synaptic plasticity of the hippocampus and protect the integrity of neurons due to its enhanced activity; NMDA receptor antagonists can enhance their ability to regulate glutamate channels due to their increased activity, thereby slowing down neuronal damage and improving cognitive function; cholinesterase inhibitors can more easily enter the synaptic cleft due to their enhanced activity, and maintain a higher drug concentration, better inhibiting the activity of cholinesterase, increasing the concentration of acetylcholine in the synaptic cleft, and improving neurotransmission.

[0016] 3. Since the activity of the drug is enhanced after heating, the drug's permeability is increased, and the drug fully flows into the patient's lesion site to treat the patient. Since the vascular endothelium of normal tissue is intact and has low permeability, the concentration of the drug in normal tissue is relatively low. Therefore, such a design reduces the damage of the drug to normal tissue, reduces the side effects of the drug, and thus reduces the side effects of the patient. And the use of heat therapy can affect the metabolism of the drug into active groups in the liver and lesion mitochondria or affect the inactivation of the active components by the liver and kidneys. The drug is heated before injection, which helps the metabolism and excretion of the drug and reduces the residual time of the drug in the body. And the heating of the drug will reduce the toxicity of the drug, further reduce the side effects of the drug, improve the tolerance of the patient, make the drug feel better, and have a wider range of applications.

[0017] 4. Since patients are often in a state of tension during drug injection, which causes muscle tension and inconvenience in injection, a care component is designed to heat the patient's injection site to make the patient feel comfortable, reduce the patient's uneasiness and tension, and relax the muscles, which is convenient for drug injection and absorption, thereby achieving better treatment effects. Since drugs are often prone to produce a large number of side effects after use, patients need to be observed and treated for side effects after the drug reaction is complete. Since heating the drug and the patient's injection site increases drug activity, when the patient has symptoms such as dizziness, vomiting, diarrhea, and physical fatigue, the medical staff adjusts the temperature regulator to cool down the indoor environment, reduce the patient's side effects, and avoid serious side effects causing secondary damage to the patient.

[0018] Further, in step five, the injection device includes a drug-loaded syringe and a pushing assembly located above the drug-loaded syringe for extracting and injecting the drug, a heating assembly for heating the drug is installed on the outer wall of the drug-loaded syringe, a care assembly for heating care is installed at the bottom of the drug-loaded syringe, and a disposable needle is detachably connected to the bottom of the drug-loaded syringe.

[0019] The beneficial effects of the basic scheme are: medical staff splice the disposable needle to the bottom of the drug-loaded syringe, push the pushing assembly under the drug-loaded syringe, exhaust the air in the drug-loaded syringe, insert the disposable needle into the medicine bottle, slowly pull up the pushing assembly, and draw CIAC001, NMDA receptor antagonist and cholinesterase inhibitor into the drug-loaded syringe.

[0020] Medical staff activate the heating component to heat the medicine to enhance its activity, fit the care component to the patient's injection site, and perform heating care on the injection site to relax the patient's muscles while also heating and disinfecting the injection site.

[0021] The medical staff then inserts the disposable needle into the patient's injection site, pushes the push component, and injects the drug into the patient's body, thereby treating the patient and achieving a therapeutic effect.

[0022] The detachable disposable needle ensures the recyclability of the injection device body and the safety of drug injection, avoiding contamination caused by repeated use of the same needle.

[0023] Furthermore, the pushing component includes a pushing head, a pushing rod is fixedly connected to the bottom of the pushing head, a piston is fixedly connected to the bottom of the pushing rod, an image identifier is installed at the bottom of the piston, the piston is slidably connected to the inner wall of the drug-loaded syringe, and an intelligent computing system for calculating the complete reaction time of the drug is provided at the top of the pushing head.

[0024] The beneficial effects of the basic solution are: when extracting drugs, the medical staff pulls up the push head, the push head drives the push rod upward, the piston moves upward with the push rod, and due to the effect of pressure change, the drug is adsorbed into the drug-loaded syringe. When injecting drugs, the medical staff pushes the push head, the push head drives the push rod downward, the piston moves downward with the push rod, and the drug is squeezed into the patient's body. Compared with only using the push rod to push the piston, this design has a larger area of ​​the push head, allowing medical staff to push the push rod more labor-saving, so that the piston extracts the drug into the drug-loaded syringe or injects the drug into the patient's body, making the drug extraction more comprehensive and the drug injection more sufficient, thereby achieving better treatment effects.

[0025] The image recognizer can effectively identify the amount of drug extracted and injected, thereby helping medical staff to accurately grasp the amount of drug, making the treatment more targeted and accurate.

[0026] Furthermore, the heating component includes a pulse coil, which is detachably connected to the outer wall of the drug-carrying syringe, to which the outer wall of the drug-carrying syringe is detachably connected with an insulating sleeve, and the drug-carrying syringe passes through the insulating sleeve, a power supply is provided in the insulating sleeve, and the pulse coil is electrically connected to the power supply.

[0027] The beneficial effect of the basic scheme is: using the principle of electromagnetic induction, using a power supply and a pulse coil to electrically connect, the current signal periodically emitted by the power supply is converted into heat energy through the pulse coil, thereby heating the medicine in the medicine-carrying syringe.

[0028] Due to the high peak current and short pulse time of the pulse signal, the heating process can concentrate a large amount of energy in a short time, so that the drug in the drug-carrying syringe is quickly heated, so that the drug has a large amount of activity in a short time, making the injection device more practical and more efficient. Since the frequency, amplitude and other parameters of the pulse signal are easy to adjust, the heating process can be accurately controlled to ensure the stability of the heating effect and heating quality, so that the heating temperature can be better controlled and the heating time can be easily controlled, so as to achieve better drug activity stimulation and efficacy enhancement effects.

[0029] The outer wall of the drug-loaded syringe is detachably connected with an insulation sleeve, which can wrap the drug-loaded syringe and the pulse coil to prevent heat loss, and also isolate the influence of the external temperature of the insulation sleeve on the drug heating process, so as to better control the temperature, and also protect the drug-loaded syringe and the pulse coil, and reduce the damage caused by collision to the drug-loaded syringe and the pulse coil. And because the insulation sleeve blocks the temperature generated by heating, the medical staff can hold the insulation sleeve, which is convenient for the medical staff to clamp and fix the device when extracting and injecting the drug, so as to better extract and inject the drug.

[0030] Furthermore, the pulse coil is spiral-shaped.

[0031] The beneficial effect of the basic scheme is that the pulse coil is in a spiral shape, which can more evenly pulse heat the medicine in the medicine-carrying syringe, so that the medicine is heated evenly and the activity of the medicine is uniform, thereby achieving a better therapeutic effect. At the same time, compared with the ring structure, the spiral structure is a whole from top to bottom, which is easy to install and reduces costs.

[0032] Furthermore, the nursing component includes a heat absorbing plate fixed circumferentially at the bottom of the medicine-carrying syringe, a plurality of ultraviolet lamps are installed on the inner wall of the heat absorbing plate, a sealing gasket is fixedly connected to the bottom of the heat absorbing plate, the heat absorbing plate is made of thermal insulation material, and the heat absorbing plate is conical.

[0033] The beneficial effects of the basic solution are: due to the heat conduction effect, the heat of the drug-carrying syringe will be transferred to the heat absorbing plate, so that the temperature of the heat absorbing plate will rise. Covering the heat absorbing plate at the position where the patient injects the drug can effectively heat the heat absorbing plate for care, and make the patient feel comfortable through the appropriate temperature, thereby reducing the patient's discomfort and tension, and relaxing the patient's inner emotions and muscles, so as to better perform the drug injection. At the same time, the ultraviolet light is turned on to disinfect and sterilize the injection site to enhance the safety of the injection.

[0034] The heat absorbing plate is set to a cone shape, and the larger bottom structure makes the heating range wider, thereby achieving a better heating care effect. Due to the stability of the triangle, the heat absorbing plate structure can also better provide support for the entire device, thereby stably treating the patient.

[0035] The sealing gasket can reduce the friction between the heat absorbing plate and the patient's skin, making the patient more comfortable, and also avoids the high temperature of the heat absorbing plate from directly contacting the patient's skin, preventing the patient from feeling uncomfortable due to excessive temperature.

[0036] Furthermore, the intelligent computing system includes a controller and a display installed on the top of the push head. The controller is connected to the display and the power supply by signals. The controller controls the power supply to start, and the power supply energizes the pulse coil. The pulse coil is energized to convert electrical energy into heat energy to heat the medicine.

[0037] The beneficial effect of the basic solution is that the display can show the remaining drug amount, heating temperature and heating time, making it easier for medical staff to control the entire drug heating and injection process in a digital way.

[0038] Medical staff can intelligently control the on and off of the power supply through the controller, and each time the medicine is heated, the temperature sensor will transmit the received temperature signal to the controller, and the image recognizer will transmit the collected liquid level information to the controller. The controller will record the amount of medicine injected each time, the heating temperature and the heating time. The controller processes the medicine heating temperature, heating time and the corresponding medicine amount according to the collected temperature signal and height information, and records them at the same time. The complete drug reaction time is calculated according to the heating time, heating temperature and medicine temperature change required for the different medicine amounts processed, and then the complete drug reaction time of different medicine amounts calculated in the past is judged according to the complete reaction time of different medicine amounts during each treatment, and the complete drug display time is transmitted to the display for display, so that medical staff can judge the medicine effects produced by different heating temperatures and different heating times according to the heating time, heating temperature and medicine temperature change, and at the same time, provide more detailed treatment and observation for patients according to the complete drug reaction time calculated by the controller.

[0039] The controller will also record the temperature change from the maximum temperature reaction to the minimum temperature after the drug is heated, as well as the change time. The controller predicts the temperature change of the drug each time based on the historical temperature change prediction and change time, thereby assisting medical staff in judging the change in drug activity and the time for the drug to fully react, so as to better provide drug treatment to patients, and also facilitate medical staff to better observe and deal with side effects.

[0040] Furthermore, a temperature sensor is installed in the thermal insulation sleeve, and the temperature sensor is connected to the controller signal.

[0041] The beneficial effects of the basic solution are: the temperature sensor can detect the temperature changes of the medicine in the medicine-carrying syringe, transmit the temperature data to the controller, and the controller processes the temperature data and transmits it to the display for display, so that medical staff can monitor the temperature changes of the medicine in the medicine-carrying syringe during the heating process in real time. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 Schematic diagram of the application method of the cannabidiol analog CIAC001 in the preparation of a drug for treating Alzheimer's disease in an embodiment of the present invention.

[0043] Figure 2 Schematic diagram of the injection device in an embodiment of the present invention.

[0044] Figure 3 This is a cross-sectional view of the drug-carrying needle tube in an embodiment of the present invention.

[0045] Figure 4 It is a top view of the pushing head in the embodiment of the present invention. DETAILED DESCRIPTION

[0046] The following is further described in detail through specific implementation methods:

[0047] The figure marks in the drawings of the specification include: a push head 1, a push rod 2, a support ring 3, a drug-loaded syringe 4, a pulse coil 5, a heat absorbing plate 6, a needle 7, a piston 8, an image recognizer 9, an ultraviolet lamp 10, an insulating sleeve 11, a controller 12, and a display 13.

[0048] The embodiment is basically as shown in the attached Figure 1-Figure 4 As shown:

[0049] The use of cannabidiol analog CIAC001 in the preparation of a drug for treating Alzheimer's disease comprises the following steps:

[0050] Step 1: Drug extraction: CIAC001, NMDA receptor antagonist and cholinesterase inhibitor were extracted into the injection device at a ratio of 1:5:5;

[0051] Step 2: Heating the medicine: starting the heating component to pulse heat the medicine in the injection device to heat the medicine to a specified temperature value;

[0052] Step 3: Patient care: heating care of the patient's injection site;

[0053] Step 4: Injection of the drug: Aim at the injection site of the patient and inject the drug into the patient's body;

[0054] Step 5: Observation and treatment of side effects: Observe the side effects of the patient and cool down the patient.

[0055] The injection device includes a drug-loaded syringe 4 and a pushing assembly located above the drug-loaded syringe 4 for extracting and injecting drugs. A heating assembly for heating drugs is welded to the outer wall of the drug-loaded syringe 4. A nursing assembly for heating care is adhered and fixed to the bottom of the drug-loaded syringe 4. A disposable needle 7 is integrally formed at the bottom of the drug-loaded syringe 4 to ensure the recyclability of the injection device body and the safety of drug injection, and to avoid contamination caused by repeated use of the same needle 7.

[0056] The pushing assembly includes a pushing head 1, a pushing rod 2 is adhered and fixed to the bottom of the pushing head 1, a piston 8 is adhered and fixed to the bottom of the pushing rod 2, the piston 8 is slidably connected to the inner wall of the drug-carrying syringe 4, and an image identifier 9 is installed at the bottom of the piston 8. The preferred model of the image identifier 9 is WEA-X5. The image identifier 9 can judge the amount of medicine according to the height of the medicine in the drug-carrying syringe 4, thereby helping medical staff to accurately grasp the amount of medicine, making the treatment more targeted and accurate.

[0057] A support ring 3 is adhered and fixed on the top of the medicine-carrying syringe, and the support ring 3 is slidably matched with the push rod 2. The support ring 3 can provide support for the push rod 2, so that the push rod 2 is more stable when pushed, which is convenient for medical staff to extract and inject drugs. When the drug is extracted, the medical staff pulls the push head 1, and the push head 1 drives the push rod 2 to move up, and the piston 8 moves up with the push rod 2. Due to the effect of pressure change, the drug is adsorbed into the medicine-carrying syringe 4. When the drug is injected, the medical staff pushes the push head 1, and the push head 1 drives the push rod 2 to move down, and the piston 8 moves down with the push rod 2, and the drug is squeezed into the patient's body. Compared with only using the push rod 2 to push the piston 8, such a design has a larger area of ​​the push head 1, so that the medical staff can push the push rod 2 more labor-savingly, so that the piston 8 extracts the drug into the medicine-carrying syringe 4 or injects the drug into the patient's body, so that the drug extraction is more comprehensive and the drug injection is more sufficient, thereby achieving a better therapeutic effect.

[0058] The heating component includes a pulse coil 5, which is fixedly adhered to the outer wall of the drug-carrying syringe 4, to which an insulating sleeve 11 is fixedly adhered, and the drug-carrying syringe 4 passes through the insulating sleeve 11. The pulse coil 5 is located between the insulating sleeve 11 and the drug-carrying syringe 4, and a power source is fixedly adhered inside the insulating sleeve 11. The pulse coil 5 is electrically connected to the power source. The pulse coil 5 is spiral-shaped, and uses the principle of electromagnetic induction. The power source is electrically connected to the pulse coil 5, and the current signal periodically emitted by the power source is converted into heat energy through the pulse coil 5, thereby heating the medicine in the drug-carrying syringe 4.

[0059] Due to the high peak current and short pulse time of the pulse signal, the heating process can concentrate a large amount of energy in a short time, so that the medicine in the medicine-carrying syringe 4 is quickly heated, so that the medicine has a large amount of activity in a short time, improves the drug efficacy, and makes the injection device more practical and more efficient in heating. Since the frequency, amplitude and other parameters of the pulse signal are easy to adjust, the heating process can be accurately controlled to ensure the stability of the heating effect and heating quality, so that the heating temperature can be better controlled and the heating time can be easily controlled, so as to achieve better drug activity stimulation and drug efficacy enhancement effects.

[0060] The heat-insulating sleeve 11 can wrap the medicine-carrying syringe 4 and the pulse coil 5 to prevent the loss of heat, and at the same time, it can also isolate the influence of the external temperature of the heat-insulating sleeve 11 on the medicine heating process, so as to better control the temperature, and also protect the medicine-carrying syringe 4 and the pulse coil 5, and reduce the damage caused by collision to the medicine-carrying syringe 4 and the pulse coil 5. And because the heat-insulating sleeve 11 blocks the temperature generated by heating, the medical staff can hold the heat-insulating sleeve 11, which is convenient for the medical staff to clamp and fix the device when extracting and injecting the medicine, so as to better extract and inject the medicine.

[0061] The nursing component includes a heat absorbing plate 6 fixedly adhered to the bottom of the drug-carrying syringe 4 in the circumferential direction, and a sealing gasket is adhered and fixed to the bottom of the heat absorbing plate 6. The heat absorbing plate 6 is made of heat-insulating material and is conical. Due to the heat conduction effect, the heat of the drug-carrying syringe 4 will be conducted to the heat absorbing plate 6, so that the temperature of the heat absorbing plate 6 increases. The heat absorbing plate 6 is covered on the position where the patient injects the drug, and the heat absorbing plate 6 can be effectively heated and cared for. The patient feels comfortable through the appropriate temperature, thereby reducing the patient's discomfort and tension, and relaxing the patient's inner emotions and muscles, so as to better perform the drug injection. Several ultraviolet lamps 10 are fixedly adhered to the inner wall of the heat absorbing plate 6, and the ultraviolet lamps 10 are started at the same time to disinfect and sterilize the injection site and enhance the safety of the injection. The heat absorbing plate 6 is set to a cone, and the larger bottom structure makes the heating range wider, thereby achieving a better heating and nursing effect. Due to the stability of the triangle, the structure of the heat absorbing plate 6 can also better provide support for the entire device, thereby stably treating the patient. The sealing gasket can reduce the friction between the heat absorbing plate 6 and the patient's skin, making the patient more comfortable, and also avoids the high temperature of the heat absorbing plate 6 from directly contacting the patient's skin, preventing the patient from feeling uncomfortable due to excessive temperature.

[0062] An intelligent computing system for calculating the complete reaction time of the drug is provided on the top of the push head 1. The intelligent computing system includes a controller 12 and a display 13 welded to the top of the push head 1. The controller 12 is preferably of model RWG1.M12D. The controller 12 is signal-connected to the display 13 and the power supply. The controller 12 controls the power supply to start, and the power supply energizes the pulse coil 5. The pulse coil 5 is energized to convert electrical energy into heat energy to heat the drug.

[0063] The display 13 can display the remaining amount of the drug, the heating temperature and the heating time of the drug. Each time the drug is heated, the temperature sensor will transmit the received temperature signal to the controller 12, and the image recognizer 9 will transmit the collected liquid level information to the controller 12. The controller 12 processes the drug heating temperature, heating time and corresponding drug amount according to the collected temperature signal and height information, and records them at the same time. The drug complete reaction time is calculated according to the heating time, heating temperature and drug temperature change required for the processed different drug amounts, and then the drug complete reaction time of different drug amounts calculated in the past is judged according to the complete reaction time of different drug amounts during each treatment, and the drug complete display time is transmitted to the display 13 for display, so that medical staff can judge the drug effects produced by different heating temperatures and different heating times according to the heating time, heating temperature and drug temperature change, and at the same time, the patient can be treated and observed more carefully according to the drug complete reaction time calculated by the controller 12.

[0064] The controller 12 will also record the temperature change and change time from the maximum temperature reaction to the minimum temperature after the drug is heated. The controller 12 predicts the temperature change of the drug each time based on the historical temperature change prediction and change time, thereby assisting medical staff in judging the change in drug activity and the time for the drug to fully react, so as to better provide drug treatment to patients, and also facilitate medical staff to better observe and deal with side effects.

[0065] Since the diameter of the drug-carrying shell is fixed, the image recognizer 9 can recognize the height of the drug. The image recognizer 9 transmits data to the controller 12. The controller 12 calculates the drug amount according to the drug height. The controller 12 calculates the heating temperature and heating time of different drug amounts through the temperature sensor, and records and learns them. During each treatment, the heating time and heating temperature of the same historical drug amount are extracted and transmitted to the display 13. The display 13 provides the medical staff with the predicted heating time and heating temperature of the drug amount. At the same time, the controller 12 provides the estimated drug complete reaction time based on the drug complete reaction time of the same historical drug amount, and transmits it to the display 13 for display. The medical staff observes the patient according to the estimated time to observe whether the patient has any adverse reactions within the drug complete reaction time. If the patient has adverse reactions, the medical staff will treat the patient for side effects, lower the indoor temperature, and alleviate the drug activity in the patient.

[0066] A temperature sensor is fixedly bonded inside the heat-insulating sleeve 11, and the temperature sensor is connected to the controller 12 by signal. The temperature sensor can detect the temperature change of the medicine in the medicine-carrying syringe 4, and transmit the temperature data to the controller 12. The controller 12 processes the temperature data and transmits it to the display 13 for display, so that medical staff can monitor the temperature change of the medicine in the medicine-carrying syringe 4 in real time during the heating process.

[0067] The temperature regulator is connected to the controller 12 by signal, so that the medical staff can lower the indoor temperature according to the degree of the patient's side effects.

[0068] 1. Experimental Preparation

[0069] Experimental group: patients treated with this method.

[0070] Control group 1: patients treated with this method, but without heating the drug.

[0071] Control group 2: patients treated with this method, but no treatment for side effects was performed on the patients.

[0072] Control group 3: patients treated with this method, but no heating care was given to the patients.

[0073] Picture recall method: prepare 20 pictures, and provide 10 pictures to the patient for memorization for 10 minutes. Name these 10 pictures memory pictures, and mix the remaining 10 pictures that are not provided to the patient for memorization into them. Name these 10 pictures non-memory pictures. Ask the patient to find the corresponding 10 memory pictures, and the memory pictures and non-memory pictures in each group are consistent. Judge the patient's memory based on the accuracy rate.

[0074] 2. Experimental Results

[0075] Table 1 Conditions of each group after treatment

[0076]

[0077] The experimental group consisted of 5 males and 5 females, with an age range of 61-65 years old and an average age of 63 years old. The accuracy of the picture recall method was 76%. Among the side effects, 4 people had mild vomiting and 6 people had no adverse reactions. The experimental group had a high accuracy rate and mild side effects.

[0078] Control group 1 consisted of 5 males and 5 females, with an age range of 60-65 years old and an average age of 62 years old. The accuracy of the picture recall method was 42%. Among the side effects, 6 people had mild vomiting, 2 people had dizziness and fatigue, and 2 people had diarrhea. The accuracy of control group 1 was reduced by 24% compared with the experimental group. The accuracy was low, and the number of side effects increased significantly. It was judged that the drug efficacy was poor and the side effects were strong due to the failure to heat the drug. Therefore, it was concluded that heating the drug can effectively improve the efficacy and reduce the side effects of the drug, thereby achieving better therapeutic effects.

[0079] Control group 2 consisted of 5 males and 5 females, with an age range of 62-64 years old and an average age of 63 years old. The accuracy of the picture recall method was 70%. Among the side effects, 2 people vomited, 7 people had dizziness and fatigue, and 1 person had diarrhea. The accuracy of control group 2 was reduced by 6% compared with the experimental group, which was a small difference. However, the number of side effects increased significantly, and there were more patients with dizziness and fatigue. It was judged that since the side effects of the patients were not treated, after the drug fully reacted, the activity was not reduced, a large number of side effects were produced, resulting in enhanced side effects in the patients. Therefore, it was concluded that side effect treatment for patients can effectively reduce drug side effects and reduce patient side effects, thereby achieving better treatment effects.

[0080] The control group 3 consisted of 5 males and 5 females, with an age range of 61-64 years old and an average age of 62 years old. The accuracy of the picture recall method was 60%. Among the side effects, 5 people had mild vomiting and 5 people had no adverse reactions. The accuracy of the control group 3 was reduced by 16% compared with the experimental group. The accuracy was low, and the side effects were very similar to those of the experimental group. It was judged that the patients' tension and anxiety were not relieved due to the lack of heating care, their muscles were tense, and it was inconvenient for medical staff to inject drugs, which reduced the penetration and absorption of drugs. Therefore, it was concluded that heating care for patients can effectively improve patients' tension and anxiety, relax patients' muscles, allow medical staff to better inject drugs, facilitate drug absorption and penetration, and achieve better treatment effects.

[0081] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.

[0082] The above is only an embodiment of the present invention. The common sense such as the known specific structure and characteristics in the scheme is not described in detail here. The ordinary technicians in the relevant field know all the common technical knowledge in the technical field of the invention before the application date or priority date, can obtain all the existing technologies in the field, and have the ability to apply the conventional experimental means before that date. The ordinary technicians in the relevant field can improve and implement this scheme in combination with their own abilities under the enlightenment given by this application. Some typical known structures or known methods should not become obstacles for ordinary technicians in the relevant field to implement this application. It should be pointed out that for those skilled in the art, without departing from the structure of the present invention, several deformations and improvements can be made, which should also be regarded as the protection scope of the present invention, which will not affect the effect of the implementation of the present invention and the practicality of the patent. The protection scope required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.

Claims

1. The use of cannabidiol analog CIAC001 in the preparation of a drug for treating Alzheimer's disease, characterized in that: The following steps are involved: Step 1, drug extraction: CIAC001, NMDA receptor antagonist and cholinesterase inhibitor were extracted into the injection device at a ratio of 1:5:5; Step 2, heating the medicine: starting the heating component to pulse heat the medicine in the injection device to heat the medicine to a specified temperature value; Step 3: Patient care: heating care of the patient's injection site; Step 4: Injection of the drug: Aim at the injection site of the patient and inject the drug into the patient's body; Step 5. Observation and treatment of side effects: Observe the side effects of the patient and cool down the patient.

2. The use of the cannabidiol analog CIAC001 according to claim 1 in the preparation of a drug for treating Alzheimer's disease, characterized in that: In step five, the injection device includes a drug-loaded syringe and a pushing assembly located above the drug-loaded syringe for extracting and injecting the drug, a heating assembly for heating the drug is installed on the outer wall of the drug-loaded syringe, a care assembly for heating care is installed at the bottom of the drug-loaded syringe, and a disposable needle is detachably connected to the bottom of the drug-loaded syringe.

3. The use of the cannabidiol analog CIAC001 according to claim 2 in the preparation of a drug for treating Alzheimer's disease, characterized in that: The pushing assembly includes a pushing head, a pushing rod is fixedly connected to the bottom of the pushing head, a piston is fixedly connected to the bottom of the pushing rod, an image identifier is installed at the bottom of the piston, the piston is slidably connected to the inner wall of the drug-loaded syringe, and an intelligent calculation system for calculating the complete reaction time of the drug is provided on the top of the pushing head.

4. The use of the cannabidiol analog CIAC001 according to claim 3 in the preparation of a drug for treating Alzheimer's disease, characterized in that: The heating component includes a pulse coil, which is detachably connected to the outer wall of the drug-loaded syringe. The outer wall of the drug-loaded syringe is detachably connected with an insulating sleeve, and the drug-loaded syringe passes through the insulating sleeve. The pulse coil is located between the insulating sleeve and the drug-loaded syringe. A power supply is provided in the insulating sleeve, and the pulse coil is electrically connected to the power supply.

5. The use of the cannabidiol analog CIAC001 according to claim 4 in the preparation of a drug for treating Alzheimer's disease, characterized in that: The pulse coil is spiral-shaped.

6. The use of the cannabidiol analog CIAC001 according to claim 5 in the preparation of a drug for treating Alzheimer's disease, characterized in that: The nursing component includes a heat absorbing plate fixed circumferentially at the bottom of the medicine-carrying syringe, a plurality of ultraviolet lamps are installed on the heat absorbing plate, a sealing gasket is fixedly connected to the bottom of the heat absorbing plate, the heat absorbing plate is made of thermal insulation material, and the heat absorbing plate is conical.

7. The use of the cannabidiol analog CIAC001 according to claim 6 in the preparation of a drug for treating Alzheimer's disease, characterized in that: The intelligent computing system includes a controller and a display installed on the top of the push head. The controller is connected to the display and the power supply by signals. The controller controls the power supply to start, and the power supply energizes the pulse coil. The pulse coil is energized to convert electrical energy into heat energy to heat the medicine.

8. The use of the cannabidiol analog CIAC001 according to claim 7 in the preparation of a drug for treating Alzheimer's disease, characterized in that: A temperature sensor is installed in the heat-insulating sleeve, and the temperature sensor is connected with the controller signal.

9. The use of the cannabidiol analog CIAC001 according to claim 8 in the preparation of a drug for treating Alzheimer's disease, characterized in that: In step five, adverse reactions refer to reactions caused by side effects of drugs, including dizziness, vomiting, diarrhea and physical fatigue.

10. The use of the cannabidiol analog CIAC001 according to claim 9 in the preparation of a drug for treating Alzheimer's disease, characterized in that: In step five, the temperature regulator is connected to the controller signal. When the patient is not observed to experience dizziness, vomiting, diarrhea and physical fatigue, the indoor temperature is kept unchanged. When the patient has side effects, the indoor temperature is lowered to 26-16 degrees according to the degree of the patient's side effects.

Images